CompletedNCT04932434
A pilot study of psilocybin for depression and anxiety in Parkinson’s
About this title
Read the official source — NCT04932434Medication studyAges 40–75United States
Understand this study
Who was this study for?
Listed age limits: 40 years to 75 years.
- Listed locations
- San FranciscoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 15, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Joshua Woolley, MD, PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 40 Years to 75 Years
- Official registry ID
- NCT04932434
- Official title
Show the full official title
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
San Francisco
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Joshua Woolley, MD, PhD.
Who was this study for?
Listed age limits: 40 years to 75 years.
